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Abstract:
Background and aim: The Trabecular Bone Score (TBS) is an index of bone microarchitectural texture 
calculated from antero-posterior DXA scans of the lumbar spine (LS) that predicts fracture risk, 
independent of BMD. The aim of this study was to compare the effects of yearly intravenous zoledronate 
(ZOL) versus placebo (PLB) on LS BMD and TBS in postmenopausal women with osteoporosis. 
Materials and Methods: Changes in TBS were assessed in the subset of 107 patients recruited at the 
Department of Osteoporosis of the University Hospital of Berne, Switzerland, who were included in the 
HORIZON trial. All subjects received adequate calcium and vitamin D3. In these patients randomly 
assigned to either ZOL (N=54) or PLB (N=53) during 3 years, BMD was measured by DXA and TBS 
assessed by TBS iNsight (v1.9) at baseline and 6, 12, 24, and 36 months after treatment initiation. 
Results: Baseline characteristics (mean ± SD) were similar between groups in terms of age, 76.8 ± 5.0 
years; BMI, 24.5 ± 3.6 kg/m2; TBS 1.178 ± 0.1 but for LS T-score (ZOL –2.9 ± 1.5 vs. PLB -2.1 ± 1.5). 
Changes in LS BMD were significantly greater with ZOL than with PLB at all-time points (p<0.0001 for 
all), reaching +9.58% vs. +1.38% at month 36. Change in TBS was significantly greater with ZOL than 
with PBO as of month 24, reaching +1.41 vs. -0.49% at month 36; p = 0.031, respectively. LS BMD and 
TBS were weakly correlated (r = 0.20), and there were no correlations between changes in BMD and TBS 
from baseline at any visit. 
Conclusions: In postmenopausal women with osteoporosis, once-yearly intravenous ZOL therapy 
significantly increased LS BMD relative to PLB over three years and TBS as of two years. 
Keywords: OSTEOPOROSIS, Bone densitometry < QUANTITATION, Bisphosphonates < 
TREATMENTS
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INTRODUCTION
Over the past two decades, the significant burden of osteoporosis has been increasingly 
recognized, in terms of patient morbidity and mortality, health care utilization, and societal costs 
(1-5). Osteoporosis is a skeletal disease characterized by low bone mass and deterioration in bone 
micro-architecture that results in enhanced bone fragility and increased susceptibility to fractures 
(6). Bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA), is the current 
reference standard for the diagnosis of osteoporosis (6-9). Fracture risk continuously increases 
with decreasing BMD, which is one of its strongest predictors (9-11). However, the greatest 
limitation of BMD measurement is that a considerable degree of overlap exists in BMD values 
between individuals with and those without subsequent fractures (12,13). This observation is 
witness to the fact that BMD is not the only structural determinant of bone strength. Trabecular 
bone microarchitecture, for example, also appears to be a significant determinant of bone 
strength, complementary to bone density (14,15).
The trabecular bone score (TBS) is a novel gray-level texture measurement that is based on the 
analysis of two-dimensional (2D) projection images that can be extracted from DXA images. The 
TBS is capable of differentiating between two 3-dimensional (3D) microarchitectures of 
cancellous bone that exhibit the same bone density but different trabecular characteristics 
(16,17). TBS values, as evaluated from 2D projection DXA images, demonstrate highly 
significant correlations with the 3D characteristics of trabecular bone microarchitecture, 
independent of BMD (16-18). A low TBS value has been found to be associated with degraded 
bone microarchitecture, low connectivity, high trabecular spacing, and a reduced number of 
trabeculae; conversely, a high TBS value has been found to be associated with good bone 
microarchitecture, including high connectivity, low trabecular spacing, and an augmented 
number of trabeculae (17,18). Hence, high values of TBS reflect strong, fracture-resistant 
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microarchitecture, while low TBS reflects weak, fracture-prone microarchitecture (16,17,19,20).
Cancellous bone microarchitectural texture assessed by TBS was a predictor of osteoporotic 
fracture risk independent of spine and hip BMD in a retrospectively analyzed prospective cohort 
of 29,407 women, age 50 years or more, living in the Province of Manitoba, Canada. 
Furthermore, in this study, combining the TBS with BMD was superior to either TBS or BMD 
alone, with regard to fracture risk prediction (21).
Based on the positive results in several fracture endpoint trials, aminobisphosphonates have 
become the mainstay of antiresorptive treatment aimed at reducing the risk of vertebral and non-
vertebral, including hip, fractures in postmenopausal women with osteoporosis (22-24). As such, 
yearly infusions of 5 mg of zoledronate (ZOL), a third-generation aminobisphosphonate, showed 
pronounced anti-fracture efficacy in the HORIZON fracture endpoint trial, producing significant 
reductions in new vertebral, non-vertebral, and hip fractures over a 3-year period in 
postmenopausal women with osteoporosis (24). This fracture risk reduction was consistent with 
improvements in BMD observed at the lumbar spine (LS) and the hip; but the order of magnitude 
of fracture risk reduction exceeded that expected from BMD changes alone (24,25). Micro-CT 
analyses of iliac crest bone biopsies performed in a subset of patients included in the HORIZON 
trial showed that patients treated with ZOL during 3 years had significantly higher trabecular 
bone volume and number of trabeculae, significantly lower trabecular separation, and 
numerically higher connectivity density, suggesting better preservation of trabecular structure 
with ZOL than with placebo (PLB) (26). These findings were consistent with observations 
performed in ovariectomized rats, which showed that decreases in trabecular architectural 
parameters were dose-dependently attenuated by ZOL and accompanied by dose-related 
improvements in bone strength parameters (27).
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The effects of ZOL on the TBS, a non-invasive method for the in situ determination of 
intravertebral cancellous bone microarchitectural texture, are unknown. The aim of the present 
study was to compare the effects of yearly intravenous ZOL and PLB during 3 years, both on LS 
BMD and site-matched bone microarchitectural texture assessed by TBS.
MATERIALS AND METHODS 
The study was performed by retrospectively assessing DXA images to calculate TBS in the full 
subset of 107 postmenopausal women with osteoporosis recruited at the Department of the 
University Hospital of Berne, Switzerland, who were included in the HORIZON trial, a 
randomized, double-blind, placebo-controlled study comparing the effects of once-yearly 
intravenous ZOL and PLB over 3 years. All patients gave additional written informed consent to 
a local BMD sub study, which had been approved by the Cantonal Ethical Committee of Berne, 
Switzerland, as a local amendment to the protocol. TBS analysis was predefined and approved by 
the institutional board of the University Hospital of Berne, Switzerland. 
Study population 
The HORIZON trial was a (1:1) randomized, double-blind, placebo-controlled clinical trial that 
compared the effects of once-yearly intravenous ZOL versus PLB in postmenopausal women 
with osteoporosis. In the original study, a total of 7765 patients were treated after random 
assignment to a once-yearly infusion over 15 minutes of either ZOL 5mg (N=3889) or PLB 
(N=3876) for a total length of follow-up of 3 years. All patients received adequate calcium and 
vitamin D3 supplementation. Major outcomes of the HORIZON trial were fracture incidence, 
change in BMD, and drug safety and tolerability. Full details on the HORIZON trial design and 
results were published earlier (24).
Patients included in the present study were the subset of all patients randomized and included in 
the HORIZON trial at the participating center of the Department of Osteoporosis of the 
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University Hospital of Berne, Switzerland, corresponding to 107 postmenopausal women with 
osteoporosis treated with either ZOL (N=54) or PLB (N=53) over 3 years.
Measurement of trabecular bone score (TBS) 
DXA images (Hologic QDR 4500ATM, Hologic Inc., Bedford, MA) of the anteroposterior LS 
(L1-4) - collected at baseline, and at follow-up evaluations 6, 12, 24, and 36 months after the 
initiation of intravenous ZOL or PLB treatment - were sent to the Bone Disease Unit of the 
University Hospital of Lausanne, Switzerland, for blinded calculation of TBS values using TBS 
iNsight® Software version 1.9; Med-Imaps, Bordeaux, France. TBS was evaluated in the same 
regions of measurement as those used for the LS BMD, with TBS calculated as the mean value 
of the individual measurements for vertebrae L1-L4 from the original DXA scans, excluding any 
fractures or degenerative changes, in accordance with ISCD rules for individual vertebrae 
exclusion (more than 1 standard deviation from immediately adjacent vertebrae) (28). As a 
result, in the PLB group, 30 patients with all vertebrae, 15 with 3 vertebrae, and 7 with 2 
vertebrae were included with one patients being excluded because only one vertebra was 
assessable. In the ZOL group, 23 patients with all vertebrae, 26 with 3 vertebrae, and 4 
with 2 vertebrae were included with 1 patient excluded because only one vertebra was 
assessable. The majority of the exclusions were related to degenerative changes in L4. All 
analyses were performed on the same vertebrae for both BMD and TBS parameters so that 
the results can be directly compared. Previously reported precision for TBS ranged 
between 1.48% (in house data) and 2.1% (21). At the Department of Osteoporosis of the 
University Hospital of Berne, the coefficient of variation for LS BMD measurements 
assessed in accordance with ISCD recommendations (15 outpatients representative of daily 
routine with triplicate measurements after repositioning) is 0.90% with a corresponding 
coefficient of variation of 1.12% for TBS. Thus, the Least Significant Change (LSC) is 
2.49% for LS BMD and 3.10% for TBS.  
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Statistical analysis 
After checking for normality distribution descriptive analysis included means and percentages 
with standard deviations.  Change in BMD and TBS from baseline were calculated for each 
subject as the absolute change divided by the baseline value and converted into a percentage. 
Bivariate inter-group comparisons were performed using Student’s t-test and Pearson’s Ȥ2
analysis for continuous variables. Data were analyzed on an intention-to-treat basis. The 
threshold for statistical significance was set at p < 0.05; and all inferential tests were two-tailed.
All statistical analyses were performed using Stata (Version 12, StataCorp LP., Texas, USA).
RESULTS
As shown in table 1, baseline characteristics (mean ± SD) were similar between groups in terms 
of age, 76.8 ± 5.0 years; BMI, 24.5 ± 3.6 kg/m2; TBS 1.178 ± 0.1 but for LS T-score (ZOL –
2.9 ± 1.5 vs. PLB -2.1 ± 1.5; p=0.01). These baseline characteristics were generally consistent 
with the mean values reported in the full population of the HORIZON trial (24).
Because of exclusion, no show, or inability to retrieve the DXA scans, the number of 
subjects varied by visit, as shown in figure 1. 
As shown in table 2 and figure 1, changes in LS BMD were significantly greater with ZOL 
than with PLB at all time points (29), reaching +2.59% vs. +0.04% and +9.58% vs. +1.38% 
at months 6 and 36, respectively (p<0.0001 for all). The change in TBS was of significantly 
larger magnitude with ZOL compared to PLB at month 24 (+1.11% vs. -0.45%; p=0.049) 
and month 36 (+1.41% vs. -0.49%, p=0.031). Compared to baseline, TBS increased 
significantly with ZOL at month 24 and 36 (+1.11%; p< 0.05, and +1.41%; p<0.04, 
respectively) but was not significantly different from baseline with PLB at any time point.  
TBS showed a slightly greater sensitivity than BMD (26 vs. 19%; McNemar-test p<0.6) 
with regard to the proportion of patients below LSC in the PLB group. As expected, BMD 
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was more sensitive than TBS with regard to the proportion of patients achieving an 
increase above LSC in treated patients (96 vs. 35%; p<0.001). 
Over three years, LS BMD and TBS were only weakly correlated (r = 0.20); and there were no 
significant correlations between the change in BMD and TBS from baseline at any follow-up 
time point.  
DISCUSSION
In the present prospectively defined retrospective analysis of the full subset of women with 
postmenopausal osteoporosis randomized to once-yearly infusions of either ZOL or PLB in the 
HORIZON-study center of the Department of Osteoporosis of the University Hospital of Berne, 
Switzerland, ZOL induced a significantly larger sustained increase in LS BMD over 36 months 
and allowed for preservation of bone microarchitectural texture assessed by TBS at month 36. 
Furthermore, BMD and TBS were only weakly correlated.  
TBS is a novel tool for fracture risk assessment in postmenopausal women (21). Its primary 
value beyond BMD is that it may specifically assess some dimensions of vertebral bone 
microarchitectural texture, which is recognized to be an important determinant of bone strength 
independent of BMD (12,14,30,31). Several studies have demonstrated that TBS was 
strongly correlated with 3D micro-architecture parameters (such as Bone Volume / 
Trabecular Volume (BV/TV), Connectivity Density, Trabecular Number (TbN), 
Trabecular Thickness (TbTh), Trabecular Spacing (TbSp), Structure Model Index (SMI)) 
as assessed by using high resolution CT (93 microns) (17,18), micro CT (35 microns) (32).
Correlations remained significant even at low resolution (33). Using TBS accurately 
differentiated between two 3D samples in which the amount of bone was identical, but 
characteristics differed with regard to TbN, TbTh, or TbSp (18). More recently, Roux et al. 
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(32) compared the TBS with microarchitectural parameters measured using microCT with 
a 35-µm isotropic resolution on lumbar vertebrae (L3) freshly harvested from 16 human 
donors. The TBS was significantly correlated to the BV/TV and the SMI (which reflects the 
rodlike versus platelike nature of the structure) with correlations coefficients of r=0.518 
(p=0.040) and -0.597 (p=0.015), respectively. They concluded that TBS was significantly 
correlated to the most relevant microarchitectural parameters used to predict fracture risk 
(i.e.; BV/TV and SMI), might improve bone assessment in association with BMD using 
standard DXA, and could enhance fracture risk assessment without requiring µCT 
acquisitions in elderly patients. In summary, an elevated TBS reflects strong, fracture-
resistant microarchitecture; a low TBS reflects weak, fracture-prone microarchitecture. 
TBS is therefore not a physical measurement but rather an index of the trabecular pattern 
of the measured bone strongly related to bone strength. 
In the current study, we sought to establish whether TBS was useful for monitoring the 
effectiveness of anti-osteoporosis therapy beyond BMD within the context of a randomized 
clinical trial. In the subset of the patient population intended for BMD analysis in the initial 
HORIZON trial, the between group difference in LS BMD over 36 months measured by DXA 
was 7.0% (p<0.01) (34) which is consistent with the between-group difference observed in the 
present analysis (8.20%, p<0.0001). While BMD increased by 9.58% vs. baseline with ZOL 
over 3 years, TBS increased by only 1.41%, which corresponds to a change ratio of 
approximately 7. This finding is consistent with recent observations made in a retrospective 
analysis of the cohort included in the large provincial database in Manitoba, Canada, in which 
most of the women treated against osteoporosis used a bisphosphonate and in which the change 
in BMD over three years approximated 2% per year, versus 0.2% per year for TBS (35).
Furthermore, in the present study, changes in BMD and in TBS were not correlated, supporting 
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the findings of previously-published research according to which the two parameters are 
measuring different characteristics of bone (21,35).
Once-yearly intravenous ZOL was shown to be significantly superior to PLB with regard to the 
reduction of vertebral and non-vertebral fracture risk, including at the hip (24,36). However, the 
order of magnitude of fracture risk reduction exceeded that expected from BMD changes alone
(25,34). The analysis of iliac crest bone biopsies performed in a subset of HORIZON trial 
patients by micro-CT identified significantly better preservation of trabecular structure with ZOL 
than with PLB (26) and microspectroscopy analysis of these biopsies showed an increased 
mineral/matrix ratio with a larger proportion of younger bone tissue with ZOL compared with 
PLB (37). These findings suggest that ZOL may exert its fracture risk reduction effects by 
increasing bone mass and by preserving bone quality in terms of bone microarchitecture and 
bone material properties. These findings are consistent with the improvements in TBS vs. 
baseline observed with ZOL but not with PLB during 3 years. 
This study can be considered a first step towards establishing a possible role for TBS in the 
monitoring of osteoporosis therapy at the individual patient level, which would suppose 
known precision and least significant change (38). In the present study, the LSC was 3.1% 
for TBS, leading to 35% of treated patients being above LSC. Precision reported in this 
study is better than the generally reported precision for LS TBS reported in the literature 
which ranges from 1.5% to 2.1% (21). This difference may be explained by the stringent 
training received by all technicians as well as by the specific study procedures required by 
the HORIZON trial. Although 35% of treated patients showed a significant TBS increase 
consistent with a microarchitectural texture improvement, 65% remained below LSC such 
that the overall effects of ZOL on bone trabeculae can be considered as a preservation of 
vertebral microarchitectural texture in the majority of patients (35,39).
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In several studies (16,19-21), TBS has been found: 1) to be lower in postmenopausal women 
with a past osteoporotic fracture relative to age- and BMD-matched women without fracture; 2) 
to, as it decreases, incrementally increase the odds ratio for spine fracture when combined with 
LS BMD; 3) to be lower in women with fractures, irrespective of whether their BMD meets the 
criteria for osteoporosis or osteopenia; 4) to prospectively predict fracture as well as LS BMD; 
and 5) to capture roughly one third of fractures misclassified using the BMD-dependent WHO 
definition of osteoporosis alone. With this study being considered as a first step, further 
studies with other bone active substances, such as teriparatide, are needed to elucidate 
whether, and if so to what extent, the combination of BMD and TBS assessments may 
contribute to improve monitoring of osteoporosis treatment at the individual patient level.
The present study has some limitations due to the retrospective nature of the analysis. However, 
the analysis was predefined and performed by intention to treat by persons blinded to treatment 
allocation and patient characteristics. The analysis was applied to the complete subset of a large 
population of postmenopausal women with osteoporosis included in a randomized, placebo-
controlled trial by a single center. Finally, baseline characteristics of patients included in the 
present analysis were comparable to those of the full patient population included in the 
HORIZON trial. While the subset of 107 patients was large enough for comparing the effects of 
ZOL vs. PLB on TBS, it was not for establishing the predictive value of TBS alone or in 
combination with BMD with regard to fracture risk. 
CONCLUSIONS
In a prospectively defined retrospective analysis of a subset of postmenopausal women with 
osteoporosis included in the HORIZON fracture endpoint trial by a single center, once-yearly 
intravenous ZOL therapy significantly increased LS BMD relative to PLB over three years 
and TBS as of two years. Change in BMD and TBS were not correlated, confirming that TBS 
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reflects bone properties other than BMD, more specifically bone microarchitectural texture. 
Further research is warranted to delineate the value of TBS as an index of treatment-related anti-
fracture effects, as well as to explore the effects of other classes of bone active substances on 
TBS.
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Table 1: Baseline characteristics (mean ± SD) 
Variable
ZOL 
(N=54)
PLB
(N=53)
P
value
Age (years) 76.6 ±  4.8 77.0 ±  5.2 ns
Height (cm) 157.8 ±  6.3 156.7 ± 4.8 ns
Weight (kg) 61.3 ±  9.4 60.0 ±  9.0 ns
BMI (kg/m2) 24.6 ±  3.3 24.5 ±  3.8 ns
Lumbar spine TBS 1.176 ±  0.11 1.181 ±  0.09 ns
Lumbar spine T-score -2.9 ±  1.5 -2.1 ±  1.5 0.01
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Table 2: Comparisons between lumbar spine BMD and TBS changes in ZOL vs. PLB 
treated women through 36 months follow-up (mean ± SEM) 
Change from baseline 
BMD
Change from baseline 
TBS
month 
PLB ZOL
P value
PLB vs. 
ZOL
PLB ZOL
P value
PLB vs. 
ZOL
0 0% 0% 0% 0% 
6 +0.04% (± 0.5) +2.59% (± 0.38)*+ <0.0001 -0.66% (± 0.54) -0.38% (± 0.49) ns
12 +0.38% (± 0.6) +4.96% (± 0.5)*+ <0.0001 -0.36% (± 0.63) +0.03% (± 0.69) ns
24 +1.70% (± 0.7)* +7.88% (± 0.5)*+ <0.0001 -0.45% (± 0.68) +1.11% (± 0.64)* 0.049
36 +1.38% (± 0.9)* +9.58% (± 0.6)*+ <0.0001 -0.49% (± 0.62) +1.41% (± 0.79)* 0.031
SEM = standard error of the mean 
* Significantly different from baseline p<0.05 
+ Significantly different from previous visit p<0.05 
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Fig. 1: BMD and TBS changes in ZOL vs. PLB treated women through 36 months 
of follow-up 
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